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Abstract
Background: Identifying early stages of hypersensitivity pneumonitis (HP) is ham-
pered by variable presentation, heterogeneous or undetected causal antigens and 
lack of gold-standard biomarkers. Krebs von den Lungen (KL)-6 is pathophysiological 
biomarker of alveolar epithelial damage. Pigeon fanciers, susceptible to HP, provide a 
model to investigate early HP.
Objective: To test the hypothesis that plasma concentrations of KL-6 are increased 
in early-stage acute HP.
Methods: Clinical history, spirometry and blood samples were obtained from pigeon 
fanciers, 20 with intermittent acute symptoms indicative of developing HP, 27 with 
no symptoms and 10 healthy subjects with no avian exposure. Plasma KL-6 (units/mL) 
and pigeon antigen-specific IgG antibody were quantified by enzyme immunoassay. 
Blood lymphocytes were quantified by flow cytometry and antigen specificity by in 
vitro cytokine production.
Results: KL-6 was higher in fanciers than controls, median (IQR) 452 (244, 632) vs 274 
(151, 377), P = .01. Although fanciers with symptoms had similar antigen exposure 
and lung function, they had higher KL-6 than those without, 632 (468, 1314) vs 320 
(200, 480), P < .001. KL-6 correlated with IgG antibody titre in those with symptoms, 
r = .591, P = .006. High KL-6, irrespective of symptom category, was associated with 
higher antibody (P = .006) and lymphocyte proliferation (P = .041), and lower CD4+ 
T lymphocyte proportion (P = .032).
Conclusion and Clinical Relevance: Raised KL-6 is associated with acute symp-
toms of early-stage HP, and its correlation with antibody may support therapeutic 
strategies when HP is suspected. KL-6 may act as a mechanistic biomarker of early 
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1  | INTRODUC TION
Early detection of hypersensitivity pneumonitis (HP) is crucial for 
prompt intervention.1,2 This can be compromised by heteroge-
neous clinical presentation and delay in identifying often cryptic 
causal antigens3,4; meanwhile, HP can become insidious and prog-
ress to treatment-refractory chronic cHP.5 Objective tests to assess 
the pathophysiological significance of early mild symptoms would 
provide timely biomarkers for subjects at-risk of progression. This 
knowledge gap in the pathogenesis of early HP may be addressed by 
investigating HP among pigeon fanciers. This population is at known 
risk for HP, where the causal exposure to antigenic dust from pi-
geons and the immune hypersensitivity responses can be measured, 
along with clinical responses. These include interstitial inflammation 
and restrictive lung dysfunction causing shortness of breath,6 and 
acute symptoms described as influenza-like with pyrexia and my-
algia suggest systemic inflammation.7 The determinants of these 
outcomes are unresolved, for example persistently raised serum IgG 
antibody against pigeon antigens can occur in asymptomatic fanci-
ers suggesting that antibody may be necessary but not sufficient for 
progression.4 Additional biomarkers indicative of a pathophysiolog-
ical response may help explain early progression.
Krebs von den Lungen-6 (KL-6) is a mucinous extracellular 
high-molecular-weight (~200kDa) sialylated glycoprotein fragment 
of the transmembrane mucin MUC-1 (CD227), classified as cluster 
9 of lung tumour and differentiation antigens.8,9 It is expressed on 
the apical surface of type 2 alveolar epithelial cells (AEC2).10 KL-6 is 
cleaved at the cysteine bond near the epithelial membrane surface, 
released into lung lining fluid and is measurable in BAL fluid.11 KL-6 
diffuses into the circulation11,12 providing evidence of increased 
lung epithelial/endothelial permeability.12,13,14AEC2 replicate ho-
meostatically to replace alveolar epithelial cells and proliferate to 
repair damaged alveolar epithelium, for example in pulmonary alve-
olar proteinosis10 and following oxidative stress and epithelial apop-
tosis in ILD including IPF and cHP.15 The density of AEC2 reflects 
the severity of recent alveolar damage16; therefore, the associated 
increased KL-6 production measured in plasma may be a sensitive 
indicator of alveolitis. In ILD, plasma KL-6 is a particularly useful 
molecular biomarker, with concentrations reflecting disease activ-
ity,2 severity8 and the effectiveness of corticosteroid therapy8,17-19 
conferring value as a diagnostic and prognostic biomarker of pro-
gression or survival.20 In a study of ILD, HP had the highest BALF 
KL-6 and the most prominent alveolitis compared with IPF and sar-
coidosis, and the serum KL-6 correlated with BALF KL-6, albumin 
and lymphocyte counts, particularly cytotoxic CD8 T cells.21,22
High concentrations of serum KL-6 have been reported in diag-
nosed HP associated with domestic23 and occupational24,25 envi-
ronments. KL-6 is higher in acute than chronic HP26 suggesting that 
alveolitis may already be prominent early in the disease trajectory 
of HP. We hypothesized that KL-6 may be an early biomarker of HP 
and tested this among undiagnosed pigeon fanciers with intermit-
tent acute symptoms associated with antigen exposure. We identi-
fied an endotype of increased KL-6 associated with IgG antibody and 
lymphocyte profile, linking lung pathophysiology with immunity that 
was indicative of early HP in this at-risk population.
2  | METHODS
2.1 | Participants
Participants were recruited at a community-based cross-sectional 
study of early-stage acute HP at a national convention of pigeon fan-
ciers where our clinical research team provided advice about pigeon 
fancier's lung, colloquial for hypersensitivity pneumonitis. Those inter-
ested to participate were fully informed of the detail and purpose of the 
study and provided signed informed consent. All information collected 
was anonymized and linked by a unique study number for each person. 
Information collected included details of age, brief relevant medical 
history, cigarette smoking history and cumulative exposure to pigeons 
(years keeping pigeons, numbers of pigeons kept and the average 
number of hours per week in contact). Ethics application for this study 
titled Data Collection in Extrinsic Allergic Alveolitis (Hypersensitivity 
Pneumonitis) was approved on 13 March 2001 (Approval Number 
00/44) by the Research Ethics Committee, Stobhill NHS Trust, Glasgow 
G21 3UW. Each participant completed a structured questionnaire su-
pervised by respiratory physicians with expertise in HP and familiarity 
with the culture of pigeon fanciers. They recorded their recollection 
of any of the following symptoms: dyspnoea, influenza-like symp-
toms, chest tightness, cough, polymyalgia, fever, fatigue, diaphoresis 
and wheeze, occurring 4-12 hours after exposure to undue amounts 
of pigeon dust (eg cleaning-out pigeon loft and/or during the moult 
when feathers are shed copiously), that resolved usually by the next 
day. A history of at least one respiratory symptom simultaneously with 
at least one systemic symptom on at least three occasions in the last 
year was recorded. Although this was insufficient for a diagnosis of 
HP,3,6 for the purposes of this study this symptom profile was used 
to categorize a group with “early-stage acute” HP27,28 who reported 
recurrent episodes of acute symptoms after contact with pigeons, that 
resolved quickly, but who had not (yet) had an established diagnosis of 
pathogenesis by linking lung pathophysiological changes with an endotype of immune 
hypersensitivity.
K E Y W O R D S
biomarkers, hypersensitivity pneumonitis, ILD, KL-6
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HP by a hospital specialist or general practitioner. We excluded those 
who did not currently keep pigeons, anyone with symptoms sugges-
tive of a recent respiratory tract infection or any current symptoms, 
those with a history of any respiratory disease or co-morbid conditions 
(such as heart disease), those who were taking anti-inflammatory medi-
cations, those with a history of a dusty occupation and current and 
recent ex-smokers (within the last 10 years). We also excluded those 
with an established diagnosis of HP after medical investigations as we 
wished to focus on those with early stage or subclinical disease. Of 
155 interviewed, 47 pigeon fanciers fulfilled study criteria and were 
enrolled; 20 had a history of acute symptoms indicative of early-stage 
acute HP, and 27 subjects had a history of no symptoms. These sub-
jects performed pulmonary function spirometry and donated a 7 mL 
heparin blood sample. A control group of 10 volunteers from the re-
search study team who fulfilled the same exclusion criteria but without 
any significant avian exposure donated a 7 mL blood sample.
2.2 | Measurement of pigeon antigen-specific 
IgG antibody
The predominant species-specific antigen in the respirable dust in pi-
geon lofts is pigeon serum gamma-globulin,29 and the subjects’ anti-
body activity against this antigen was measured by indirect enzyme 
immunoassay (EIA).30 Briefly, 96-well polystyrene microtitre EIA 
plates (Dynatech Ltd, UK) were coated with purified antigen (donated 
by Dr P. Lynch); 5 μg/mL in bicarbonate buffer (0.02 mol/L, pH 9.6), 
100 μL/well 24 hour at 4ᵒC. Plate wells were washed three times in 
detergent buffer (phosphate-buffered saline, 0.02 mol/L, pH7.4, con-
taining 0.05% Tween-20, PBS-T). Plasma samples were diluted opti-
mally at 1:200 with PBS-T and incubated in duplicate at 100 μL/well 
for 1 hour at room temperature, after which the plates were washed 
as above. Bound antibody was quantified using alkaline phosphatase 
conjugated anti-human IgG at 1:10 000 dilution in PBS-T (Sigma, UK). 
After washing as before, the plate wells were incubated with the col-
ourless substrate p-nitrophenyl phosphate (Sigma, UK) at 1 mg/mL in 
10% diethanolamine, pH10. This is converted by enzyme activity to a 
yellow product with an absorbance at 405 nm. After approximately 
30 minutes, the optical density was measured by spectrophotometer 
(Dynatech Ltd UK). If all other reagents are in excess, the E405 nm was 
proportional to the antibody activity and this was quantified by inter-
polation using an optical density standard curve from serial dilutions 
of a standard serum with known antibody concentration previously 
titrated by quantitative precipitation.
2.3 | Blood leucocyte cytology and 
lymphocyte culture
Total and differential white blood cell counts were determined by 
Coulter counter (CBC5, Coulter Electronics) and by flow cytom-
etry (FACScan, BD Biosciences, UK) using FITC-anti-CD45 and 
PE-anti-CD14 (Sigma, UK). The major T lymphocyte subsets were 
counted by FACS using FITC-anti-CD3 with either PE-anti-CD4 or 
PE-anti-CD8 (Sigma). The cell counts and proportions are listed in 
Supplementary Table S1.
Antigen-specific lymphocyte responses were measured by whole 
blood assay. Briefly, each blood bottle was resuspended by inver-
sion, and 20 μL was added to 80 μL DMEM containing penicillin 
and streptomycin (Gibco, UK) per well in 96-well cell culture plates 
(Fisher Scientific, UK). Each blood was tested in quadruplicate, with 
and without 5 μg/mL of pigeon serum gamma-globulin antigen. 
Plates were incubated at 37ᵒC in a humidified 5% CO2 atmosphere. 
After 5 days, each well was pulsed with 10 μL (0.015 MBq) tritiated 
thymidine (TRA-120, GE Healthcare, Amersham, UK) and incubated 
for a further 6 hours. Thymidine incorporation into DNA, indicative 
of lymphocyte proliferation, was measured as counts per minute 
(cpm) by beta-counter (MicroBeta Trilux, PerkinElmer) of cells har-
vested onto a glass-fibre filter mat (MicroBeta Filtermate Harvester, 
PerkinElmer, Bucks, UK). Antigen-specific lymphocyte proliferation 
was measured by subtracting the background count, obtained from 
each sample well without antigen, from the count from the corre-
sponding sample well cultured with antigen. The average of the four 
replicate counts per person was corrected for the number of lym-
phocytes in the culture well. These experiments were performed 
using Institutional Health and Safety guidelines.
2.4 | Plasma KL-6
Plasma KL-6 was measured by sandwich enzyme immunoassay 
(Eitest KL-6 kit, Sekisui Medical Co. Ltd. Japan) according to the 
manufacturer's instructions. Reference levels are listed in Table S2.
2.5 | Statistical analysis
The primary aim was to test the working hypothesis that the plasma 
KL-6 concentration was increased in pigeon fanciers with a symptom 
history indicative of risk of progression to hypersensitivity pneumonitis. 
Secondary aims included investigating linear relationships between KL-6 
with antigen exposure, lung function and immune reactivity. Variables 
were summarized as median and interquartile range; between-group 
comparisons were tested by Mann-Whitney U test. The linear relation-
ships were tested by Spearman's rho. Analysis was performed using 
Minitab software (Minitab Inc, State College, PA). Secondary aims were 
considered exploratory, and there was no correction for multiple com-
parisons. P < .05 was considered statistically significant.
3  | RESULTS
3.1 | Categorization of pigeon fanciers according to 
symptom history
Of 155 interviewed, 20 pigeon fanciers described a history of in-
termittent acute symptoms following exposure to pigeon dust 
(Methods), and 27 had a history of no symptoms (Table 1). There 
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was no difference between the “early-stage acute” and “asympto-
matic” categories for age, pigeon antigen exposure or spirometric 
lung function; therefore, these groups were considered suitable for 
a comparative investigation for biomarkers of risk of progression 
to HP.
3.2 | Blood leucocytes
Compared with control subjects (Table S1), the pigeon fanciers had 
lower total blood leucocyte counts (P = .041), and lower relative pro-
portions (P = .003) and absolute counts (P = .01) of CD8 lympho-
cytes. Within the categories of pigeon fanciers (Table 1), those with 
early-stage acute HP had a lower proportion of CD4+ lymphocytes 
(P = .045) and a higher proportion of CD8+ lymphocytes (P = .02) 
than their asymptomatic counterparts.
3.3 | Immune reactivity against pigeon antigens and 
symptom category
Pigeon fanciers had high IgG antibody (Figure 1A) and modest in 
vitro lymphocyte proliferative responses (Figure 1B) against pi-
geon antigens, that were negligible among control subjects with 
no significant avian exposure. There was no correlation between 
the IgG antibody concentration or the lymphocyte proliferative 
response with age, antigen exposure, lung function or blood cy-
tology in all pigeon fanciers and in the “early-stage acute” and 
“asymptomatic” categories (Table S3). There was a significant 
correlation between the humoral (IgG antibody titre) and the 
cellular (lymphocyte proliferation) responses, r = .429, P = .003 
(Figure S1).
Fanciers with early-stage acute HP had higher IgG antibody (μg/
mL); 61.0 (41.0, 83.5) vs 44.0 (9.0, 59.0), P = .011, and a trend towards 
greater lymphocyte proliferation (in vitro proliferation, cpm cor-
rected for lymphocyte count); 3.7 (2.0, 6.5) vs 2.5 (1.7, 3.8), P = .064, 
compared with asymptomatic fanciers. However, there were many 
asymptomatic subjects with evidence of immune reactivity, and 
several symptomatic subjects with relatively low immune reactivity 
and this overlap suggested that the immune response profile was 
insufficient to cleanly differentiate asymptomatic from early-stage 
acute HP; therefore, we investigated KL-6 as a pathophysiological 
biomarker between these categories.
3.4 | Plasma KL-6 as a pathophysiological 
biomarker of symptoms indicative of early-stage 
acute HP
There was no linear relationship between plasma KL-6 concentra-
tion and cumulative exposure to pigeon antigens, spirometric lung 
function or blood cytology (Table S3). The median (IQR) units/mL 
plasma KL-6 (Figure 2) was higher in the pigeon fanciers than in the 
control subjects with no significant avian exposure, 452 (244, 632) 
vs 274 (151, 377), P = .01, and the pigeon fanciers with early-stage 
acute HP had higher KL-6 than those without, 632 (468-1314) vs 
320 (200-480), P < .001. There was no difference in KL-6 between 
fanciers with no symptoms and control subjects, 320 (200, 480) vs 
274 (151, 377), respectively, P = .137.
The plasma concentration of KL-6 correlated with the IgG anti-
body titre r = .494, P < .001 (Figure S2). This linear relationship was 
stronger among pigeon fanciers with a history of acute symptoms 
indicative of early-stage HP, r = .591, P = .006 (Figure 3), but did not 
reach statistical significance among those without a history of acute 
symptoms (r = .180, P = .369). The KL-6 concentration did not cor-
relate with the lymphocyte proliferative response to pigeon antigens 
among all pigeon fanciers r = .250, P = .09 (Figure S3), nor in ether 
TA B L E  1   Median (IQR) describing age, indices of cumulative 
exposure to antigenic dust from pigeons (number of pigeons 
kept, number of years exposure and the average number of hours 
per week in contact with pigeons), spirometric measures of lung 
function, and blood total (106/mL) and differential leucocyte counts 
and relative proportions in pigeon fanciers comparing those with 
and without a history of acute symptoms indicative of subclinical 
HP
Variable
Symptoms indicative of early-stage 
HP
P*No (n = 27) Yes (n = 20)
Age years 53 (43, 61) 48 (41, 60) .584
Antigen exposure
Number 47 (40, 65) 60 (50, 80) .281
Years 20 (19, 39) 20 (10, 37) .45
Hours/week 16 (7, 25) 14 (7, 20) .38
Spirometrya 
FEV1 94.0 (78.0, 104) 82.0 (69.0, 99.0) .375
FVC 98.5 (79.0, 114) 91.0 (78.0, 102) .309
FEV1/FVC 94.1 (84.1, 103) 95.3 (79.8, 104) .716
FEF25-75 72.0 (50.5, 95.2) 68.0 (35.0, 101) .808
Blood cytology
Leucocytes 7.21 (6.79, 8.3) 7.52 (6.55, 8.5) .613
Neutrophils 4.59 (3.83, 5.16) 4.18 (3.42, 5.2) .624
Monocytes 0.44 (0.4, 0.52) 0.49 (0.39, 0.59) .181
Lymphocytes 2.58 (2.07, 3.01) 2.37 (2.03, 2.93) .739
CD4 1.02 (0.93, 1.34) 1.01 (0.68, 1.36) .355
CD8 0.39 (0.29, 0.5) 0.44 (0.36, 0.72) .138
% neutrophils 59.0 (54.0, 68.0) 59.0 (54.2, 62.5) .712
% monocytes 6.0 (4.0, 7.0) 7.0 (6.0, 7.0) .208
% lymphocytes 34.0 (26.0, 39.0) 35.0 (24.5, 39.0) .966
CD4% 45.0 (37.0, 51.0) 37.0 (31.5, 45.0) .045
CD8% 17.0 (13.0, 20.0) 20.0 (16.5, 27.0) .02
 aPercent-predicted forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), FEV1/ FVC ratio and forced expiratory flow 
at 25-75% of FVC (FEF25-75).  
 *Mann-Whitney U test, P < .05 considered statistically significant.  
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category of “early-stage acute” HP (r = .146, P = .539) or “asymptom-
atic” fanciers (r = .152, P = .451).
3.5 | Comparison between objective 
categories of normal and high plasma KL-6 
concentrations
A 95th centile of normality for KL-6 was calculated from control 
subjects. This generated an upper cut-off normal limit at 452 µ/mL 
which was consistent with published levels (Table S2). We used this 
to as an objective discriminator of “normal” and “high” categories of 
KL-6 and used this, rather than subjective symptom-recall, to com-
pare lung function, antigen exposure and immune response among 
the pigeon fanciers (Table 2). There was no difference in age, antigen 
exposure and lung function, but those with “high” KL-6 had higher 
antigen-specific IgG antibody titre, 59 (44, 85) vs 28.5 (11.2, 51.7) 
P = .006, and greater lymphocyte proliferation, 3.5 (2.1, 6.6) vs 2.2 
(1.5, 3.9) P = .041, and lower proportions of blood CD4 T lympho-
cytes, 41 (32, 45) vs 45 (36.2, 51) P = .032.
3.6 | Evaluation of serum KL-6 and IgG antibody 
in factory workers exposed a contaminated 
humidification system
For comparison, we conducted a serological study of KL-6 and IgG 
antibody activity among undiagnosed factory workers, some with 
acute HP symptoms associated with exposure to recognized but 
uncharacterized antigens aerosolized from the water sump of a 
F I G U R E  1   The pigeon antigen-specific IgG antibody (A) and in vitro lymphocyte proliferative response (B) in healthy control subjects 
with no significant avian exposure, and in pigeon fanciers categorized according to history of acute symptoms indicative of subclinical 
HP. Box-and-whisker plot showing median, IQR and range. Mann-Whitney U test comparing pigeon fanciers with and without a history of 
symptoms indicative of subclinical acute HP, for IgG P = .011 and for proliferation (cpm corrected for lymphocyte number), P = .065
F I G U R E  2   The plasma concentration of KL-6 in healthy 
control subjects with no significant avian exposure generated 
an upper 95 percentile of normality at 452 units/mL. Box-and-
whisker plot showing median, IQR and range. Mann-Whitney 
U test demonstrated a higher KL-6 in pigeon fanciers with a 
history of acute symptoms indicative of subclinical HP compared 
with asymptomatic counterparts (P < .001). The KL-6 values are 
indicated on a log10 scale for clearer representation. The mean 
values are superimposed as bold bars at 268, 359 and 1121 units/
mL for control healthy donors, pigeon fanciers with no symptoms 
and pigeon fanciers with a history of symptoms indicative of 
subclinical acute HP, respectively
F I G U R E  3   Linear relationship between the plasma 
concentrations of IgG antibody against pigeon antigen and KL-6 in 
pigeon fanciers with a history of symptoms indicative of subclinical 
acute HP. Spearman's rho = 0.591, P < .001
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recycling water-cooled air humidification system (Supplementary 
text and Figure S4). The factory workers had significantly higher IgG 
antibody titres compared with healthy control subjects with no an-
tigen exposure, medians (IQR) 0.987 (0.1, 1.66) vs 0.09 (0.06, 0.12), 
P < .001, M-W U test. They also had higher titres of KL-6; 615 (412, 
878) vs 320 (200, 480), P < .001. The KL-6 concentration in those 
factory workers with significantly high titres (>596 µ/mL) was lin-




To address the search for a biomarker of pathogenesis of post-ex-
posure symptoms and potential risk of progression to HP among pi-
geon fanciers, this study identified 20 candidates with an indicative 
symptom history, and 27 with no symptoms; with equivalent age, 
spirometry and pigeon antigen exposure. The pigeon fanciers with 
early-stage acute symptoms had raised plasma KL-6 commensurate 
with IgG antibody. Raised KL-6 is an objective biomarker of alveolar 
remodelling and IgG represents immune hypersensitivity, together 
demonstrating pathophysiological changes in those with early-stage 
acute HP. These observations suggest that high KL-6 has merit to 
identify at-risk pre-clinical individuals and prioritize those for further 
investigation and follow-up, and might additionally serve as an in-
terim surrogate for antibody detection in HP of unrecognized cause.
4.2 | Comparison with other studies
The published studies of KL-6 in HP generally report diagnosed 
cases. Our findings extend and complement these by investigat-
ing KL-6 in “pre-clinical” or undiagnosed early-stage acute HP. 
Our 95th centile of normality for KL-6 calculated at 453 µ/mL 
compared well with others (eg 458 µ/mL, 465 µ/mL, 500 µ/mL. 
Table S2). Among the pigeon fanciers with no symptoms, the KL-6 
at 320 (200, 480) µ/mL was not different from normal. In our pi-
geon fanciers with early-stage acute HP, the KL-6 at 632 (468, 
1314) µ/mL was higher than normal but less than levels reported 
in cases of diagnosed HP 2996 ± 2016 µ/mL23 and 1263 ± 288 µ/
mL.25 In a comparative study with different ILDs,26 median KL-6 
levels were higher in acute HP (2710 µ/mL) than chronic HP 
(1500 µ/mL), and both higher than in IPF, CVD-IP and sarcoidosis. 
In chronic HP, increasing KL-6 concentration might usefully dis-
criminate progressive from stable disease,31 whereas in acute HP, 
the KL-6 might also reflect antigen exposure. For example, differ-
ent seasonal peaks of serum KL-6 reflect different seasonal expo-
sures to either domestic or avian antigen exposures,32 and antigen 
avoidance for more than one month among bird fanciers was as-
sociated with reducing KL-6 and improved lung function.32,33An 
index case of acute pigeon fanciers HP demonstrated that raised 
KL-6 levels returned to normal after 8 months of antigen avoid-
ance17 and was indicative of long-term clinical improvement. Our 
study in pigeon fanciers with no diagnosis of HP suggests that 
raised KL-6 is associated with acute symptoms from antigen ex-
posure and alveolitis occur early in the disease trajectory of HP 
and before diagnosis.
TA B L E  2   Pigeon fanciers categorized according to normal 
(≤452 U/mL) or high (>452 U/mL) serum KL-6
KL-6 normal KL-6 high
P*n = 24 n = 23
Age years 51.5 (9.9) 51.5 (11) .982
Antigen exposure
Number 50 (40, 70) 60 (42.5, 80) .226
Years 20.0 (12.7, 39.7) 20 (12.5, 34) .913
Hour/week 14 (7, 25) 14 (7.5, 24) .967
Spirometrya 
FEV1 94 (78, 107) 81 (66, 97.5) .178
FVC 96 (79.2, 115) 92 (77.5, 108) .402
FEV1 /FVC 99.1 (91.7, 103) 89.6 (77.3, 102) .168
FEF25-75 85 (34, 101) 57 (34, 101) .206
Immunology





2.2 (1.5, 3.9) 3.5 (2.1, 6.6) .041
Blood cytology
Leucocytes 7.15 (6.72, 8.52) 7.40 (6.80, 
8.40)
.459
Neutrophils 4.49 (3.63, 5.17) 4.33 (3.44, 
5.32)
.947
Monocytes 0.44 (0.35, 0.55) 0.49 (0.43, 
0.58)
.239
Lymphocytes 2.65 (2.2, 3.0) 2.28 (1.95, 
2.94)
.45
CD4 1.09 (0.89, 1.37) 0.93 (0.68, 
1.35)
.187
CD8 0.42 (0.32, 0.59) 0.44 (0.28, 
0.65)
.915
% neutrophils 59 (54, 62.5) 59.5 (54, 70.2) .785
% monocytes 6 (4.2, 7.7) 6.5 (5.7, 7) .684
% lymphocytes 35 (27.7, 39) 33 (24, 37) .494
CD4% 45 (36.2, 51) 41 (32, 45) .032
CD8% 18 (13, 21.5) 19 (15, 24) .21
Note: Comparison of age, indices of exposure to pigeon antigens, lung 
function, immune responses measured by pigeon antigen-specific IgG 
antibody concentration and in vitro lymphocyte proliferation, and blood 
total and differential absolute counts (106/mL) and relative proportions.
 aPercent-predicted forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), FEV1/ FVC ratio and forced expiratory flow 
at 25-75% of FVC (FEF25-75).  
 *Mann-Whitney U test, P < .05 considered statistically significant.  
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4.3 | What can KL-6 reveal about the 
pathogenesis of early-stage acute HP
The pathogenic determinants of onset and progression of HP are un-
resolved. Antigen-specific antibody and cellular immune responses ap-
pear necessary but not sufficient for the development of symptoms. 
Our findings highlight KL-6 as a useful candidate biomarker for early 
progression. KL-6 produced by regenerating type-2 alveolar epithe-
lial cells (AEC2) is increased with the proliferation required to repair 
apoptotic epithelial cells associated with alveolar damage in HP.23,34 
IHC of HP lung tissue show apoptotic markers (Fas, Fas-L, p53, p21) 
on epithelial cells 23,34 and apoptotic epithelial cells can stimulate in-
duction of experimental HP by enhancing maturation of dendritic cells 
and lung adaptive immunity.34,35 In the present study, the fanciers had 
robust IgG responses to pigeon antigens but only those with raised 
KL-6 had symptoms indicative of early-stage acute HP. This suggests 
that asymptomatic pigeon fanciers, even with considerable cumulative 
exposure to pigeon antigens and a robust immune response, can have 
normal plasma KL-6 levels. Raised IgG antibody, commensurate with 
increased KL-6 we suggest is indicative of early pathophysiological 
changes and risk of clinically significant HP.
Elevated plasma KL-6 is indicative of lung remodelling. KL-6 is 
a large ~200kDa fragment shed from Muc-1 on AEC236 and raised 
plasma levels indicate increased airway epithelial permeability. 
We37 and others38 have demonstrated increased lung permeability 
in sero-positive asymptomatic pigeon fanciers, and sero-positive 
farmers without HP and increased lung permeability and raised 
serum KL-6.25 In ILD, raised KL-6 correlated with: chest Ga-67 
scintigraphy,39 degree of computed tomography,40 A-a O2 ten-
sion difference,41 severity of symptoms and chest X-ray findings, 
and inversely with PaO2 and DLco,42,43 and symptoms, opacities 
on chest radiograph, and arterial blood gases.13 Together these 
biomarkers suggest that increased serum KL-6 concentration is in-
dicative of interstitial inflammation and pathological changes, and 
levels serve as diagnostic, and prognostic biomarker of progression 
or survival.20
In pulmonary sarcoidosis, the serum KL-6 correlated with serum 
ACE44 and with BAL fluid albumin and lymphocyte proportion.45 
In chronic HP, serum KL-6 levels correlated with increased propor-
tion of BAL fluid T cells,22 and in the present study increasing KL-6 
levels trend with a decrease of circulating CD4+ T cells (r = −.279, 
P = .058), perhaps reflecting lymphocyte traffic from blood into 
inflamed lung. These observations strongly suggest that KL-6 is in-
dicative of considerable disturbances in lung pathophysiology with 
the prospect that similar disturbances might occur perhaps at lower 
levels commensurate with KL-6 levels in early-stage acute HP.
Although KL-6 is associated with changes in lung pathophysiology, 
it might directly cause pathogenic remodelling. KL-6 is chemotactic for 
human fibroblasts in vitro and may contribute to the intra-alveolar fi-
brosis in HP.46 Speculating on this observation, resolution or increase 
of KL-6 might usefully discriminate stable or progressive cHP phe-
notypes.31 HP likely has clinical phenotypes beyond the inadequate 
classification of acute, subacute and chronic.47 These phenotypes 
could be determined by combinations of immunological, for example 
antigen-specific antibody and lymphocyte activities, and remodelling 
mediators, for example KL-6. A combination of these might reflect an 
endotype of lower-lung pathology that could guide appropriate an-
ti-inflammatory or anti-fibrotic therapies. Treatment and monitoring 
of HP that is chronic with fibrosis is difficult2; therefore, therapeutic 
targeting KL-6, for example with corticosteroids early in the disease tra-
jectory, would have optimum impact to forestall fibrosis before disease 
becomes refractory and plasma KL-6 levels might identify and stratify 
HP patients for relevant therapies or trials.
4.4 | Strengths and limitations
Strength Classification of HP based on symptoms into acute, suba-
cute or chronic categories is inadequate, with subacute HP particu-
larly difficult to define.47,48 The excellent engagement with pigeon 
fanciers as a homogeneous study group at known risk of HP, and 
their familiarity with symptom patterns of “pigeon lung” helped pro-
vide well-categorized groups based on post-exposure symptoms 
which underpinned this study.
Limitations a ) The relatively low number of subjects with ear-
ly-stage acute HP reflects the reality of identifying this category of 
HP. However, it would be important to validate the findings of raised 
plasma KL-6 in an extended early-stage acute HP group with normal 
spirometry along with high-resolution CT and physiological markers 
of parenchymal changes such as transfer factor and oscillometry. b) 
Longitudinal measurement of KL-6, lung function, high-resolution 
CT and emerging symptoms from baseline KL-6 and post-exposure 
symptoms would validate KL-6 as a prognostic marker of HP. A use-
ful prototype would be the study that identified newly diagnosed 
ILD in systemic sclerosis in a follow-up of those with elevated base-
line KL-6.49 c) MUC1 rs4072037 single-nucleotide polymorphisms 
affect serum concentration of KL-6 and severity of ILD.50 Correcting 
serum KL-6 level for the MUC1 haplotypes may increase its value 
as a prognostic marker. SNP genotype analysis will be included in a 
follow-up study to address these limitations.
5  | CONCLUSION
This study demonstrated that early-stage acute HP can be identi-
fied by raised plasma KL-6, and commensurate increased antibody 
is evidence of an underlying immunological diathesis. These find-
ings should stimulate further research to facilitate and hasten the 
identification of HP and improve the clinical management and moni-
toring of individuals at-risk of HP, for example screening agricultural 
workers, and in antigen-occult HP, for example humidifier fever. 
Immunological and pathophysiological biomarkers add endotype 
evidence for dynamic clinical phenotypes. Among these, early-stage 
acute HP implicates AEC2 as an axis of homeostatic or aberrant re-
modelling and therefore a potential target for early therapeutic in-
tervention in hypersensitivity pneumonitis.
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